Morgan Stanley analyst Craig Hettenbach raised the firm’s price target on Veeva (VEEV) to $210 from $201 and keeps an Underweight rating on the shares. Veeva posted “a solid beat in Q1” and “a very strong print in the face of growing headwinds” as Veeva’s high quality business model is “shining though right now,” the analyst tells investors. However, as evidenced by negative estimate revisions to sales at various points in each of the last three years, Veeva is “not completely immune” to the “tumultuous backdrop in Life Sciences that has tripped up most companies selling into this vertical,” the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue